New Psychedelic Trials Target Depression and PTSD
Compass Pathways’ psilocybin (COMP360) for treatment-resistant depression (TRD) Usona Institute’s psilocybin for major depressive disorder (MDD) Otsuka’s methylone (TSND-201) for PTSD
Psilocybin Reconfigures Cortical Inhibition via Interneuron Recruitment
wonky / important pre-clinial paper out of Alex Kwan's lab Psilocybin reshapes cortical inhibition through selective interneuron recruitment @kwanalexc https://t.co/OZX2cHDD94
Social Support Beats Policy‑blind Trauma Treatment for Recovery
Treating trauma while ignoring the social and political conditions that generate it risks turning medicine into a repair shop for problems our policies continue to produce. The strongest predictor of sustained recovery from addiction is social support. https://t.co/HoXy8efgWf
Order Set to Speed Psychedelic Drug Research Access
the order will dramatically accelerate access to new medical research and treatments based on psychedelic drugs
HHS Partners to Boost Psychedelic Trial Data, Prioritize Breakthroughs
HHS will work with the Department of Veterans Affairs, as well as the private sector, to increase clinical trial participation, data sharing, and real-world evidence generation regarding psychedelic drugs, and shall prioritize drugs that have received Breakthrough Therapy status
First Responder Memoir: From Badge to Vineyard
memoir of a first responder FROM THE BADGE TO THE VINE free download through Bicycle Day (Sunday) https://t.co/rm2cTA5MRz
International Mega-Analysis Shows Psychedelics Alter Brain Circuit Function
An international mega-analysis of psychedelic drug effects on brain circuit function lots of great researchers involved in this paper. (whole article) https://t.co/vKhH0duJqv
Blueprint for Integrating Psilocybin Into NHS Mental Health Care
British Journal of Psychiatry Psychedelics in NHS services: exploring a model for real-world implementation of psilocybin https://t.co/6sgfqg66rt
Psychedelics Show Promise for Schizophrenia Negative Symptoms
Psychedelics for treatment of negative symptoms and depressive symptoms in schizophrenia spectrum disorder: A narrative review https://t.co/fGpTLwF3DK
LSD and DOI Reduce Opioid Intake and Withdrawal in Mice
Effects of Psychedelics Lysergic Acid Diethylamide and R(–)-2,5-Dimethoxy-4-Iodoamphetamine on Oral Opioid Consumption and Naloxone-Precipitated Withdrawal in Male C57Bl/6J Mice https://t.co/78DNsREzoR
Intranasal 5-MeO-DMT Boosts Depression Relief with SSRIs
The results of this first phase 2a clinical trial of intranasal 5-MeO-DMT administered adjunctively to SSRIs demonstrated acceptable safety and tolerability with promising improvements in depressive symptoms. https://t.co/m15DkPP4qX
Repeated Psilocybin Doses Yield 73% OCD Response
A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive–compulsive disorder 73.3% were responders (⩾35% reduction in YBOCS scores), with 40% in remission. These effects diminished but remained substantial at 6 months. https://t.co/tp2SPIKDrB
5‑MeO‑DMT Shows Promise for Treatment‑Resistant Depression
Emerging evidence supports 5-MeO-DMT as a promising, ultra-short-acting psychedelic for treatment-resistant depression and other psychiatric conditions, warranting larger randomized controlled trials. https://t.co/6CcEOSat1F
Ayahuasca Shows Mixed Impacts on Cognition and Social Insight
Effects of ayahuasca on neuropsychological performance and social cognition: A systematic review - Caio César de Paula, Anna Beatriz Vicentini, Lorena Terene Lopes Guerra, José Carlos Bouso, Jaime E. C. Hallak, Rafael G. dos Santos, 2026 https://t.co/oXP57hmeR1
Psychedelics Boost Exercise Habits and Stress Resilience
psychedelics appear to facilitate the adoption or maintenance of physical activity habits, increase psychological flexibility, emotional resilience to acute stress, exercise and psychedelics have numerous potential complementary mechanisms https://t.co/gl4YK8bqaE